Update of current therapeutic options for the treatment of postmenopausal osteoporosis

Clinical Therapeutics

Volumn 28, Issue 2, 2006, Pages 151-173

  Epstein, Solomon ^a,b  

^a Doylestown Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

bisphosphonates; efficacy; fracture; osteoporosis; postmenopausal; therapeutic options

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CARBAMAZEPINE; CLARITHROMYCIN; CLODRONIC ACID; COLESTYRAMINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ERYTHROMYCIN; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHENOBARBITAL; PROGESTERONE; RALOXIFENE; RIFAMPICIN; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TILUDRONIC ACID; UNINDEXED DRUG; VITAMIN D; WARFARIN; ZOLEDRONIC ACID;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ACUTE PHASE RESPONSE; ARTICLE; BONE DEFECT; BONE DENSITY; BONE MINERALIZATION; BREAST CANCER; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG USE; DUODENITIS; DYSPHAGIA; EPISTAXIS; ESOPHAGUS DISEASE; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FRACTURE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPOCALCEMIA; INFORMATION RETRIEVAL; KIDNEY DYSFUNCTION; LEG CRAMP; LUNG EMBOLISM; MEDLINE; MYALGIA; OSTEITIS FIBROSA; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PHLEBITIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RETINA VEIN OCCLUSION; RHINITIS; SIDE EFFECT; STROKE; ULCER; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANABOLIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VITAMIN D;

EID: 33646199229     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.02.007     Document Type: Article

References (119)

1. Consensus Development Conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 94 (1993) 646-650
2. Kanis J., Delmas P., Burckhardt P., et al., for the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and managmeent of osteoporosis. Osteoporos Int. 7 (1997) 390-406
3. Heinemann D. Osteoporosis. An overview of the National Osteoporosis Foundation clinical practice guide. Geriatrics. 55 (2000) 31-36
4. World Health Organization. Prevention and management of osteoporosis. Available at. http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf WHO Technical Report Series 921
5. Looker A., Johnston Jr. C., Wahner H., et al. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res. 10 (1995) 796-802
6. Siris E., Miller P., Barrett-Connor E., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA 286 (2001) 2815-2822
7. [published correction appears in Arch Intern Med. 1992;152:655]. Chrischilles E., Butler C., Davis C., and Wallace R. A model of lifetime osteoporosis impact. Arch Intern Med. 151 (1991) 2026-2032
8. Melton III L. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res. 15 (2000) 2309-2314
9. Miller C. Survival and ambulation, following hip fracture. J Bone Joint Surg Am. 60 (1978) 930-934
10. Salkeld G., Cameron I., Cumming R., et al. Quality of life related to fear of falling and hip fracture in older women: A time trade off study. BMJ 320 (2000) 341-346
11. Cockerill W., Lunt M., Silman A., et al. Health-related quality of life and radiographic vertebral fracture. Obsteopros Int 15 (2004) 113-119
12. O'Neill T., Cockerill W., Matthis C., et al. Back pain, disability, and radiographic vertebral fracture in European women: A prospective study. Osteoporos Int. 15 (2004) 760-765
13. Kanis J., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 35 (2004) 375-382
14. Melton III L. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 18 (2003) 1139-1141
15. Ray N., Chan J., Thamer M., and Melton III L. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res. 12 (1997) 24-35
16. Puffer S., Torgerson D., Sykes D., et al. Health care costs of women with symptomatic vertebral fractures. Bone 35 (2004) 383-386
17. Melton III L., Chrischilles E., Cooper C., et al. Perspective. How many women have osteoporosis?. J Bone Miner Res. 7 (1992) 1005-1010
18. Available at. American Cancer Society. Breast Cancer Facts and Figures (2003-2004). http://http://www.cancer.org/docroot/STT/content/STT_1x_Breast_Cancer_Facts_Figures
19. Cooper C. The epidemiology of osteoporosis. Osteoporos Int. 9 Suppl 2 (1999) S2-S8
20. Johnell O., Oden A., Caulin F., and Kanis J. Acute and longterm increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int. 12 (2001) 207-214
21. Premarin [package insert] (2005), Wyeth Pharmaceuticals, Philadelphia, Pa
22. Evista [package insert] (2003), Eli Lilly and Company, Indianapolis, Ind
23. Miacalcin [package insert] (2003), Novartis Pharmaceuticals Corporation, East Hanover, NJ
24. Actonel [package insert] (2002), Procter & Gamble Pharmaceuticals, Inc, Mason, Ohio
25. Fosamax [package insert] (2005), Merck & Co, Inc, West Point, Pa
26. Forteo for injection [package insert] (2004), Eli Lilly and Company, Indianapolis, Ind
27. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 327 (1992) 1637-1642
28. Lips P., Graafmans W., Ooms M., et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 124 (1996) 400-406
29. 3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ 326 (2003) 469-472
30. Bischoff-Ferrari H., Willett W., Wong J., et al. Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials. JAMA 293 (2005) 2257-2264
31. 3) for prevention of fractures in primary care. BMJ 330 (2005) 1003-1006
32. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebocontrolled trial. Lancet 365 (2005) 1621-1628
33. Greendale G., Espeland M., Slone S., et al., for the PEPI Safety Follow-Up Study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med. 162 (2002) 665-672
34. [published correction appears in Menopause. 2000; 7:135]. Ettinger B., Pressman A., and Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 6 (1999) 282-289
35. Steel S., Albertazzi P., Howarth E., and Purdie D. Factors affecting longterm adherence to hormone replacement therapy after screening for osteoporosis. Climateric. 6 (2003) 96-103
36. Bryant H. Mechanism of action and preclinical profile of raloxifene: A selective estrogen receptor modulator. Rev Endocr Metab Disord 2 (2001) 129-138
37. Wijayaratne A., Nagel S., Paige L., et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140 (1999) 5828-5840
38. [published correction appears in JAMA. 1999;282:2124]. Ettinger B., Black D., Mitlak B., et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
39. Delmas P., Ensrud K., Adachi J., et al., for the Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopousal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 87 (2002) 3609-3617
40. for the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Cranney A., Wells G., Willan A., et al. Meta-analyses of therapies for postmenopausal os-teoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 23 (2002) 508-516
41. for the Alendronate Once-Weekly Study Group. Schnitzer T., Bone H., Crepaldi G., et al. Therapeutic equivlence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12 (2000) 1-12
42. Sarkar S., Reginster J., Crans G., et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 19 (2004) 394-401
43. [published corrections appear in CMAJ. 2003;168:400; CMAJ. 2003:168:544; and CMAJ. 2003;168:676]. Brown J., Josse R., and for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 Suppl 10 (2002) S1-S34
44. Overgaard K., Hansen M., Jensen S., and Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ 305 (1992) 556-561
45. for the PROOF Study Group. Chesnut III C., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence Of Osteoporotic Fractures study. Am J Med. 109 (2000) 267-276
46. Cummings S., and Chapurlat R. What PROOF proves about calcitonin and clinical trials. Am J Med. 109 (2000) 330-331
47. Barrett J., Worth E., Bauss F., and Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44 (2004) 951-965
48. Gertz B., Holland S., Kline W., et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 58 (1995) 288-298
49. Sansom L., Necciari J., and Thiercelin J. Human pharmacokinetics of tiludronate. Bone 17 Suppl 5 (1995) 479S-483S
50. Mitchell D., Heise M., Pallone K., et al. The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 48 (1999) 536-542
51. Tosteson A., Grove M., Hammond C., et al. Early discontinuation of treatment for osteoporosis. Am J Med. 115 (2003) 209-216
52. Hamilton B., McCoy K., and Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 14 (2003) 259-262
53. Muhlbauer R., Bauss F., Schenk, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 6 (1991) 1003-1011
54. Russell R., and Rogers M. Bisphosphonates: From the laboratory to the clinic and back again. Bone 25 (1999) 97-106
55. Zizic T. Pharmacologic prevention of osteoporotic fractures. Am Fam Physician 70 (2004) 1293-1300
56. for the Alendronate Phase III Osteoporosis Treatment Study Group. Liberman U., Weiss S., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333 (1995) 1437-1443
57. for the Fracture Intervention Trial Research Group. Black D., Cummings S., Karpf D., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
58. Black D., and Thompson D. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract Suppl. 101 (1999) 46-50
59. Cummings S., Black D., Thompson D., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
60. Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci. 47 (2002) 1665-1678
61. Yood R., Emani S., Reed J., et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 14 (2003) 965-968
62. Kendler D., Kung A., Fuleihan G.-H., et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 48 (2004) 243-251
63. Simon J., Lewiecki E., Smith M., et al. Patient preference for onceweekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther. 24 (2002) 1871-1886
64. Recker R., Gallagher R., MacCosbe P., et al. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 80 (2005) 856-861
65. for the Alendronate Phase III Osteoporosis Treatment Study Group. Bone H., Hosking D., Devogelaer J., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 350 (2004) 1189-1199
66. Abstract 1173. Recker R., Ensrud K., Diem S., et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res. 19 Suppl 1 (2004) S45
67. Chavassieux P., Arlot M., Reda C., et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 100 (1997) 1475-1480
68. for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Harris S., Watts N., Genant H., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
69. for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Reginster J., Minne H., Sorensen O., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 11 (2000) 83-91
70. for the Hip Intervention Program Study Group. McClung M., Geusens P., Miller P., et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344 (2001) 333-340
71. Brown J., Kendler D., McClung M., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 71 (2002) 103-111
72. Delmas P., Li Z., and Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res. 19 (2004) 330-337
73. Letter. Goodman R. The effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344 (2001) 1720-1721
74. Letter. Royce P. The effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344 (2001) 1720
75. Schott A., Dargent-Molina P., and Meunier P. The effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 344 (2001) 1721
76. Rosen C., Hochberg M., Bonnick S., et al., for the Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res. 20 (2005) 141-151
77. for the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Cranney A., Guyatt G., Griffith L., et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of metaanalyses of therapies for postmenopausal osteoporosis. Endocr Rev. 23 (2002) 570-578
78. Hosking D., Adami S., Felsenberg D., et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: A randomised, placebo-controlled study. Curr Med Res Opin. 19 (2003) 383-394
79. Sorensen O., Crawford G., Mulder H., et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 32 (2003) 120-126
80. Eriksen E., Melsen F., Sod E., et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
81. Bauss F., and Russell R. Ibandronate in osteoporosis: Preclinical data and rationale for intermittent dosing. Osteoporos Int. 15 (2004) 423-433
82. Chsnut III C., Skag A., Christiansen C., et al., for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America, and Europe (BONE). Effects of oral ibandronate administed daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 19 (2004) 1241-1249
83. Delmas P., Recker R., Chesnut III C., et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteoporos Int. 15 (2004) 792-798
84. Miller P., McClung M., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. J Bone Miner Res. 20 (2005) 1315-1322
85. for the Protocol 19 Aredia Breast Cancer Study Group. Hortobagyi G., Theriault R., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 335 (1996) 1785-1791
86. Papapoulos S. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Ann Med Interne (Paris) 151 (2000) 504-510
87. [published correction appears in J Clin Pharm Ther. 2005; 30:96]. Cauza E., Etemad M., Winkler F., et al. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis. J Clin Pharm Ther. 29 (2004) 431-436
88. Fan S., Almond M., Ball E., et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 57 (2000) 684-690
89. Forin V., Arabi A., Guigonis V., et al. Benefits of pamidronate in children with osteogenesis imperfecta: An open prospective study. Joint Bone Spine. 72 (2005) 313-318
90. Green J. Preclinical pharmacology of zoledronic acid. Semin Oncol. 29 Suppl 21 (2002) 3-11
91. Chang J., Green L., and Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 349 (2003) 1676-1679
92. Rosen L., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions, of multiple myeloma: A phase III, doubleblind, comparative trial. Cancer J. 7 (2001) 377-387
93. for the Zoledronic Acid Prostate Cancer Study Group. Saad F., Gleason D., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 94 (2002) 1458-1468
94. Rosen L., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 21 (2003) 3150-3157
95. Reid I., Brown J., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 346 (2002) 653-661
96. Colon-Emeric C., Caminis J., Suh T., et al., for the HORIZOn Recurrent Fracture Trial. The HORIZOn Recurrent Fracture Trial: Design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin. 20 (2004) 903-910
97. Zometa for intravenous injection [package insert] (2005), Novartis Pharmaceuticals Corporation, East Hanover, NJ
98. Aredia for injection [package insert] (2005), Novartis Pharmaceuticals Corporation, East Hanover, NJ
99. Abstract P425SU. Sambrook P., Reginster J., Recker R., et al. Novel ibandronate regimens in postmenopausal osteoporosis: Design of the Dosing IntraVenous Administration (DIVA) study. Osteoporos Int. 15 Suppl 1 (2004) S118
100. Recker R., Stakkestad J., Chesnut III C., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34 (2004) 890-899
101. Adami S., Felsenberg D., Christiansen C., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
102. Rao D., Wilson R., Kleerekoper M., et al. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: Evidence for biphasic disease course. J Clin Endocrinol Metab. 67 (1988) 1294-1298
103. Reeve J., Arlot M., Bradbeer J., et al. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporos Int. 3 Suppl 1 (1993) 199-203
104. Frolik C., Black E., Cain R., et al. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone 33 (2003) 372-379
105. Locklin R., Khosla S., Turner R., and Riggs B. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem. 89 (2003) 180-190
106. Neer R., Arnaud C., Zanchetta J., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 344 (2001) 1434-1441
107. Rao L., and Murray T. Binding of intact parathyroid hormone to rat osteosarcoma cells: Major contribution of binding sites for the carboxyl-terminal region of the hormone. Endocrinology 117 (1985) 1632-1638
108. Hodsman A., Hanley D., Ettinger M., et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab. 88 (2003) 5212-5220
109. Harris S., Eriksen E., Davidson M., et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 86 (2001) 1890-1897
110. Greenspan S., Resnick N., and Parker R. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: A randomized controlled trial. JAMA 289 (2003) 2525-2533
111. Johnell O., Scheele W., Lu Y., et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 87 (2002) 985-992
112. Finkelstein J., Hayes A., Hunzelman J., et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 349 (2003) 1216-1226
113. Black D., Greenspan S., Ensrud K., et al., for the PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 349 (2003) 1207-1215
114. Zhou H., Shen V., Dempster D., and Lindsay R. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J Bone Miner Res. 16 (2001) 1300-1307
115. Cosman F., Nieves J., Zion M., et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 353 (2005) 566-575
116. Black D., Bilezikian J., Ensrud K., et al., for the PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 353 (2005) 555-565
117. Lindsay R., Scheele W., Neer R., et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 164 (2004) 2024-2030
118. Ettinger B., San Martin J., Crans G., and Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 19 (2004) 745-751
119. Rittmaster R., Bolognese M., Ettinger M., et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 85 (2000) 2129-2134